Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_assertion type Assertion NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_head.
- NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_assertion description "[However, independent of the presence of DR4 and DR5, TRAIL cytotoxicity assays revealed that pancreatic cancer cells showed a significantly lower sensitivity (LD(50)>85 ng/ml) to TRAIL treatment than Jurkat T lymphoma cells (LD(50)=7.2 ng/ml).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_provenance.
- NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_assertion evidence source_evidence_literature NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_provenance.
- NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_assertion SIO_000772 11163110 NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_provenance.
- NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_assertion wasDerivedFrom befree-2016 NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_provenance.
- NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_assertion wasGeneratedBy ECO_0000203 NP306088.RA4ji8-QW2Za-8rVV-0Vd6Dy7ilbLxI51pETcNtelcKQw130_provenance.